Open AccessStatins and Risk of Cholangiocarcinoma: A Systematic Review and Meta-analysis
Author(s) -
Karn Wijarnpreecha,
Elizabeth S. Aby,
Hassan Ghoz,
Wisit Cheungpasitporn,
Frank Lukens,
Denise M. Harnois,
Patompong Ungprasert
Publication year - 2020
Publication title -
journal of gastrointestinal and liver diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.641
H-Index - 48
eISSN - 1842-1121
pISSN - 1841-8724
DOI - 10.15403/jgld-2990
Subject(s) - medicine , meta analysis , odds ratio , medline , random effects model , study heterogeneity , systematic review , confidence interval , statin , political science , law
Background and Aims: The use of statins has been shown to be associated with a decreased risk of cholangiocarcinoma (CCA) in many studies although the results have been inconsistent. We conducted this systematic review and meta-analysis to further investigate this possible association by identifying all relevant studies and combining their results together.
Methods: A comprehensive literature review was conducted utilizing the MEDLINE and EMBASE databases through March 2020 to identify all studies that compared the risk of CCA among individuals who use statins with individuals who do not use statins. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird.
Results: A total of seven studies with 6,251,187 participants fulfilled the eligibility criteria and were included in this meta-analysis. The pooled analysis found a significantly decreased risk of CCA among individuals who use statins compared with individuals who do not use statins with the pooled odds ratio of 0.68 (95% CI: 0.52-0.89; I 2 96%).
Conclusions: The current systematic review and meta-analysis found a significant association between the use of statins and a decreased risk of CCA.